As previously reported, Morgan Stanley analyst Erin Wright downgraded Heska to Underweight from Equal Weight with a price target of $58, down from $135. She already had viewed Heska’s medium-term and long-term outlook as "ambitious," but underperformance in 2022 and slower than anticipated traction with its new Element AIM launch are "inevitably disappointing" and add risk to 2023 growth, Wright tells investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on HSKA:
- Dalan Animal Health granted USDA conditional license for honeybee vaccine
- Heska price target lowered to $165 from $170 at Piper Sandler
- Heska price target lowered to $119 from $155 at Alliance Global Partners
- Heska sees FY22 revenue in line with FY22 and up 5%
- Heska reports Q4 non-GAAP EPS 41c, consensus (11c)